Search Results

TSO3 Inc. (“TSO3" or the “Company”) (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, announced that the Company has initiated sterilization testing intended to support repeated sterile reprocessing in the TSO3 STERIZONE® VP4 Sterilizer of the Fujifilm ED-530XT duodenoscope supplied by FUJIFILM Medical Systems U.S.A., Inc.

TSO3 Inc. (“TSO3" or the “Company”) (TSX: TOS) today announced that is has completed the previously-announced statutory plan of arrangement under the Business Corporations Act (Québec) pursuant to which a wholly-owned subsidiary of Stryker Corporation acquired all of the issued and outstanding common shares of the Company (the “Shares”) for CAD$0.43 per share in cash (the “Arrangement”

TSO3 Inc. (TSX: TOS) (“TSO3" or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, reported financial results for the first quarter ended March 31, 2019.

TSO3 Inc. (“TSO3" or the “Company”) (TSX: TOS) confirms that the consideration payable to the shareholders of the Company (the “Shareholders”) pursuant to the plan of arrangement (the “Arrangement”) involving the Company, Stryker Corporation (“Stryker”) and 9402-4874 Québec Inc. (the “Purchaser”), a subsidiary of Stryker, continues to be CAD $0.43 per share.

TSO3 Inc. reported financial results for the third fiscal quarter ended September 30, 2018.

TSO3 Inc. announced that the nominees listed in the management proxy circular dated April 4, 2019, were elected as directors of TSO3.

TSO3 Inc. wishes to reiterate that shareholders should vote in favor of the proposed plan of arrangement involving the Company, Stryker Corporation (“Stryker”) and 9402-4874 Québec Inc.

TSO3 Inc. reported financial results for the second fiscal quarter ended June 30, 2018.

TSO3 Inc. was named the winner of the South Carolina Chamber of Commerce’s SC Branded Product Innovation Award.

TSO3 today provided an update on its 2017 operating activities.